Howe & Rusling’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Howe & Rusling’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q4	–	Sell	-178	Closed	-$11K	–	1137
2022 Q3	$11K	Buy	178 +28	+19%	+$1.96K	﹤0.01%	530
2022 Q2	$12K	Sell	150 -27	-15%	-$2.56K	﹤0.01%	515
2022 Q1	$19K	Buy	177 +90	+103%	+$8.77K	﹤0.01%	430
2021 Q4	$9K	Hold	87	–	–	﹤0.01%	564
2021 Q3	$10K	Buy	87 +17	+24%	+$1.76K	﹤0.01%	527
2021 Q2	$7K	Buy	70 +4	+6%	+$368	﹤0.01%	555
2021 Q1	$6K	Sell	66 -7	-10%	-$591	﹤0.01%	598
2020 Q4	$5K	Sell	73 -47	-39%	-$3.49K	﹤0.01%	646
2020 Q3	$9K	Buy	+120	New	+$8.26K	﹤0.01%	467

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

HBK Investments Dallas, Texas $9.85B AUM 55.6% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Howe & Rusling's HZNP Position: Q4 2022 in Review

Howe & Rusling sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q4 2022, closing a stake of 178 shares — an estimated $11K sold.

Howe & Rusling first reported a position in HZNP in Q3 2020 and held it in 9 quarters. The position peaked at $19K in Q1 2022. 615 funds tracked by Wall St. Rank hold HZNP as of Q4 2022.

Howe & Rusling reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q4 2022 after selling out during the quarter.
Howe & Rusling sold 178 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q4 2022, an estimated $11K.
Howe & Rusling first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q3 2020 and held it in 9 quarters.
Howe & Rusling's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $19K in Q1 2022.
615 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q4 2022.

Based on Howe & Rusling's 13F filing for Q4 2022, filed 15 Feb 2023.